Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The prevalence of vascular cognitive impairment (VCI) is likely to increase as the population ages and cardiovascular disease survival improves. We provide an overview of the definition and disease mechanisms of VCI and present a systematic literature review of the current evidence for the pharmacologic and nonpharmacologic therapies used to treat the VCI symptoms of cognitive dysfunction or to modify VCI through primary and secondary prevention. The Cochrane Database of Systematic Reviews was searched from 2005 to October 2010 using the keywords “vascular dementia” or “vascular cognitive impairment and therapy.” MEDLINE was searched for English-language articles published within the last 10 years using the combined Medical Subject Headings (MeSH) “therapeutics and dementia,” “vascular” or “vascular cognitive impairment.” Although cholinesterase inhibitors and memantine produce small cognitive improvements in patients with VCI, these drugs do not improve global clinical outcomes and have adverse effects and costs. Selective serotonin reuptake inhibitors and dihydropyridine calcium channel blockers may improve short-term cognitive function in patients with VCI. Anti-hypertensive therapy with an ACE inhibitor-based regimen and statins may prevent the major subtype of VCI known as poststroke cognitive decline. Clinical and effectiveness studies with long-term follow-up are needed to determine the benefits and risks of pharmacologic and nonpharmacologic therapies to prevent and treat VCI. Given its growing health, social, and economic burden, the prevention and treatment of VCI are critical priorities for clinical care and research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448 · cited 1×
“1) [37, 38].”
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“, cerebral or lacunar infarctions) [25, 26].”
Pendlebury, S. T., & Rothwell, P. M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70236-4 · Cited by 1,853 · cited 1×
“Given that recurrent stroke accelerates VCI, secondary stroke prevention is an important strategy to prevent cognitive declines in VCI [124].”
BackgroundHachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Research works printed but not linked: 85
- Lobo, 2000, Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S4
- He W, Sengupta M, Velkoff VA, DeBarros KA. U.S. Census Bureau, Current Population Reports, P23-209, 65+ in the United States: 2005, U.S. Government Printing Office,Washington, DC, 2005. · DOI
- Ukraintseva, 2006, Increasing rates of dementia at time of declining mortality from stroke, Stroke, 37, 1155, 10.1161/01.STR.0000217971.88034.e9 · DOI · Paper page
- Bowler, 1999, Conceptual background to vascular cognitive impairment, Alzheimer Dis Assoc Disord, 13, S30
- Rockwood, 2002, Societal costs of vascular cognitive impairment in older adults, Stroke, 33, 1605, 10.1161/01.STR.0000017878.85274.44 · DOI · Paper page
- Sicras, 2005, Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting, Dement Geriatr Cogn Disord, 19, 305, 10.1159/000084556 · DOI
- Hill, 2005, Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population, J Alzheimers Dis, 8, 43, 10.3233/JAD-2005-8105 · DOI · Paper page
- Boyle, 2004, Assessment and prediction of functional impairment in vascular dementia, Expert Rev Neurother, 4, 109, 10.1586/14737175.4.1.109 · DOI
- Nys, 2006, Early cognitive impairment predicts long-term depressive symptoms and quality of life after stroke, J Neurol Sci, 247, 149, 10.1016/j.jns.2006.04.005 · DOI · Paper page
- Fillit, 2002, The costs of vascular dementia: a comparison with Alzheimer's disease, J Neurol Sci, 203–204, 35, 10.1016/S0022-510X(02)00257-5 · DOI
- Knopman, 2003, Survival study of vascular dementia in Rochester, Minnesota, Arch Neurol, 60, 85, 10.1001/archneur.60.1.85 · DOI · Paper page
- Fitzpatrick, 2005, Survival following dementia onset: Alzheimer's disease and vascular dementia, J Neurol Sci, 229–230, 43, 10.1016/j.jns.2004.11.022 · DOI · Paper page
- Langa, 2004, Mixed dementia: emerging concepts and therapeutic implications, JAMA, 292, 2901, 10.1001/jama.292.23.2901 · DOI · Paper page
- Jin, 2006, The reciprocal risks of stroke and cognitive impairment in an elderly population, Alzheimers Dement, 2, 171, 10.1016/j.jalz.2006.03.006 · DOI · Paper page
- Knopman, 2009, Association of prior stroke with cognitive function and cognitive impairment: a population-based study, Arch Neurol, 66, 614, 10.1001/archneurol.2009.30 · DOI
- Tatemichi, 1993, Clinical determinants of dementia related to stroke, Ann Neurol, 33, 568, 10.1002/ana.410330603 · DOI · Paper page
- Desmond, 2002, Incidence of dementia after ischemic stroke: results of a longitudinal study, Stroke, 33, 2254, 10.1161/01.STR.0000028235.91778.95 · DOI · Paper page
- Desmond, 2000, Frequency and clinical determinants of dementia after ischemic stroke, Neurology, 54, 1124, 10.1212/WNL.54.5.1124 · DOI · Paper page
- Skoog, 1993, A population-based study of dementia in 85-year-olds, N Engl J Med, 328, 153, 10.1056/NEJM199301213280301 · DOI · Paper page
- Ahtiluoto, 2010, Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study, Neurology, 75, 1195, 10.1212/WNL.0b013e3181f4d7f8 · DOI · Paper page
- Hachinski, 2007, The 2005 Thomas Willis Lecture: stroke and vascular cognitive impairment: a transdisciplinary, translational and transactional approach, Stroke, 38, 1396, 10.1161/01.STR.0000260101.08944.e9 · DOI · Paper page
- Sachdev, 2004, The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients, Neurology, 62, 912, 10.1212/01.WNL.0000115108.65264.4B · DOI · Paper page
- Roman, 2002, Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention, Med Clin North Am, 86, 477, 10.1016/S0025-7125(02)00008-1 · DOI
- Kivipelto, 2006, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study, Lancet Neurol, 5, 735, 10.1016/S1474-4422(06)70537-3 · DOI · Paper page
- Luchsinger, 2001, Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort, Am J Epidemiol, 154, 635, 10.1093/aje/154.7.635 · DOI · Paper page
- Ravaglia, 2008, Physical activity and dementia risk in the elderly: findings from a prospective Italian study, Neurology, 70, 1786, 10.1212/01.wnl.0000296276.50595.86 · DOI · Paper page
- Iadecola, 2003, Converging pathogenic mechanisms in vascular and neurodegenerative dementia, Stroke, 34, 335, 10.1161/01.STR.0000054050.51530.76 · DOI · Paper page
- Murray, 2009, The brain and the kidney connection: A model of accelerated vascular cognitive impairment, Neurology, 73, 916, 10.1212/WNL.0b013e3181b99a2e · DOI
- Honig, 2003, Stroke and the risk of Alzheimer disease, Arch Neurol, 60, 1707, 10.1001/archneur.60.12.1707 · DOI · Paper page
- Puccio, 2009, Atrial fibrillation and mild cognitive impairment: what correlation?, Minerva Cardioangiol, 57, 143
- Purandare, 2007, Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia, Biol Psychiatry, 62, 339, 10.1016/j.biopsych.2006.12.010 · DOI
- van Oijen, 2005, Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia, Stroke, 36, 2637, 10.1161/01.STR.0000189721.31432.26 · DOI · Paper page
- Yamamoto, 2005, High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia, J Am Geriatr Soc, 53, 583, 10.1111/j.1532-5415.2005.53204.x · DOI · Paper page
- Zuliani, 2007, High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia, Int J Geriatr Psychiatry, 22, 305, 10.1002/gps.1674 · DOI · Paper page
- Ivan, 2004, Dementia after stroke: the Framingham Study, Stroke, 35, 1264, 10.1161/01.STR.0000127810.92616.78 · DOI · Paper page
- Hebert, 2000, Vascular dementia : incidence and risk factors in the Canadian study of health and aging, Stroke, 31, 1487, 10.1161/01.STR.31.7.1487 · DOI · Paper page
- Kuller, 2003, Risk factors for dementia in the cardiovascular health cognition study, Neuroepidemiology, 22, 13, 10.1159/000067109 · DOI · Paper page
- Barba, 2000, Poststroke dementia: clinical features and risk factors, Stroke, 31, 1494, 10.1161/01.STR.31.7.1494 · DOI · Paper page
- Peters, 2005, Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies, Arch Neurol, 62, 1091, 10.1001/archneur.62.7.1091 · DOI · Paper page
- Dotti, 2005, The spectrum of Notch3 mutations in 28 Italian CADASIL families, J Neurol Neurosurg Psychiatry, 76, 736, 10.1136/jnnp.2004.048207 · DOI · Paper page
- Tang, 2005, Arg332Cys mutation of NOTCH3 gene in the first known Taiwanese family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, J Neurol Sci, 228, 125, 10.1016/j.jns.2004.10.019 · DOI
- Leblanc, 2006, Genetics of vascular cognitive impairment: the opportunity and the challenges, Stroke, 37, 248, 10.1161/01.STR.0000195177.61184.49 · DOI
- Malouf, 2004, Donepezil for vascular cognitive impairment, Cochrane Database Syst Rev, 10.1002/14651858.CD004395.pub2 · DOI · Paper page
- Bores, 1996, Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine, J Pharmacol Exp Ther, 277, 728, 10.1016/S0022-3565(25)12928-5 · DOI · Paper page
- Maelicke, 2000, Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease, Eur J Pharmacol, 393, 165, 10.1016/S0014-2999(00)00093-5 · DOI · Paper page
- Craig, 2006, Galantamine for vascular cognitive impairment, Cochrane Database Syst Rev
- Craig, 2005, Rivastigmine for vascular cognitive impairment, Cochrane Database Syst Rev
- Gardoni, 2006, New targets for pharmacological intervention in the glutamatergic synapse, Eur J Pharmacol, 545, 2, 10.1016/j.ejphar.2006.06.022 · DOI
- Kornhuber, 1994, Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties, J Neural Transm Suppl, 43, 91
- Qaseem, 2008, Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians, Ann Intern Med, 148, 370, 10.7326/0003-4819-148-5-200803040-00008 · DOI · Paper page
- O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol published online 18 November 2010. 10.1177/0269881110387547. The online version of this article can be found at: http://jop.sagepub.com/content/early/2010/11/17/0269881110387547 · DOI · Paper page
- Wong, 2009, Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia, Can J Neurol Sci, 36, 735, 10.1017/S0317167100008350 · DOI
- Meyer, 1986, Improved cognition after control of risk factors for multi-infarct dementia, JAMA, 256, 2203, 10.1001/jama.1986.03380160061021 · DOI · Paper page
- Tzourio, 2003, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease, Arch Intern Med, 163, 1069, 10.1001/archinte.163.9.1069 · DOI · Paper page
- Bosch, 2002, Use of ramipril in preventing stroke: double blind randomised trial, BMJ, 324, 699, 10.1136/bmj.324.7339.699 · DOI · Paper page
- Lithell, 2003, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens, 21, 875, 10.1097/00004872-200305000-00011 · DOI · Paper page
- Diener, 2008, Lancet Neurol, 7, 875, 10.1016/S1474-4422(08)70198-4 · DOI · Paper page
- Qiu, 2005, The age-dependent relation of blood pressure to cognitive function and dementia, Lancet Neurol, 4, 487, 10.1016/S1474-4422(05)70141-1 · DOI · Paper page
- Wang, 2009, Blood Pressure and Brain Injury in Older Adults: Findings from a Community-Based Autopsy Study, J Am Geriatr Soc, 57, 1975, 10.1111/j.1532-5415.2009.02493.x · DOI · Paper page
- Lopez-Arrieta, 2002, Nimodipine for primary degenerative, mixed and vascular dementia, Cochrane Database Syst Rev
- Moretti, 2008, Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia, Am J Alzheimers Dis Other Demen, 23, 167, 10.1177/1533317507312558 · DOI
- Broe, 2000, Anti-inflammatory drugs protect against Alzheimer disease at low doses, Arch Neurol, 57, 1586, 10.1001/archneur.57.11.1586 · DOI · Paper page
- Meyer, 1989, Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study, J Am Geriatr Soc, 37, 549, 10.1111/j.1532-5415.1989.tb05688.x · DOI · Paper page
- Williams, 2000, Aspirin for vascular dementia, Cochrane Database Syst Rev
- Dufouil, 2005, APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study, Neurology, 64, 1531, 10.1212/01.WNL.0000160114.42643.31 · DOI · Paper page
- Moroney, 1999, Low-density lipoprotein cholesterol and the risk of dementia with stroke, JAMA, 282, 254, 10.1001/jama.282.3.254 · DOI · Paper page
- Collins, 2004, Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions, Lancet, 363, 757, 10.1016/S0140-6736(04)15690-0 · DOI · Paper page
- Richard, 2009, Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial, J Am Geriatr Soc, 57, 797, 10.1111/j.1532-5415.2009.02217.x · DOI · Paper page
- Richard, 2009, Moll van Charante EP, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress, Alzheimer Dis Assoc Disord, 23, 198, 10.1097/WAD.0b013e31819783a4 · DOI · Paper page
- Fioravanti, 2005, Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly, Cochrane Database Syst Rev, 10.1002/14651858.CD000269.pub3 · DOI · Paper page
- Cohen, 2003, Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes, Cerebrovasc Dis, 16, 199, 10.1159/000071116 · doi:10.1159/000071116
- Alvarez-Sabin, 2011, Citicoline in vascular cognitive impairment and vascular dementia after stroke, Stroke, 42, S40, 10.1161/STROKEAHA.110.606509 · DOI
- Olin, 2001, Hydergine for dementia, Cochrane Database Syst Rev
- Napryeyenko, 2007, Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial, Arzneimittelforschung, 57, 4
- Hao, 2009, Huperzine A for vascular dementia, Cochrane Database Syst Rev, 10.1002/14651858.CD007365.pub2 · DOI
- Frampton, 2003, Propentofylline for dementia, Cochrane Database Syst Rev, 10.1002/14651858.CD002853 · DOI · Paper page
- Banasr, 2004, Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone, Neuropsychopharmacology, 29, 450, 10.1038/sj.npp.1300320 · DOI · Paper page
- Royall, 2009, Sertraline improves executive function in patients with vascular cognitive impairment, J Neuropsychiatry Clin Neurosci, 21, 445, 10.1176/jnp.2009.21.4.445 · DOI · Paper page
- De Rango, 2008, The role of carotid artery stenting and carotid endarterectomy in cognitive performance: a systematic review, Stroke, 39, 3116, 10.1161/STROKEAHA.108.518357 · DOI
- Rockwood, 2007, Physical activity and the maintenance of cognitive function, Alzheimers Dement, 3, S38, 10.1016/j.jalz.2007.01.003 · DOI · Paper page
- Quaney, 2009, Aerobic exercise improves cognition and motor function poststroke, Neurorehabil Neural Repair, 23, 879, 10.1177/1545968309338193 · DOI · Paper page
- Friedman, 1988, CARDIA: study design, recruitment, and some characteristics of the examined subjects, J Clin Epidemiol, 41, 1105, 10.1016/0895-4356(88)90080-7 · DOI · Paper page
- Hajjar, 2009, The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition, BMC Geriatr, 9, 48, 10.1186/1471-2318-9-48 · DOI · Paper page
- Williamson, 2007, The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods, Am J Cardiol, 99, 112i, 10.1016/j.amjcard.2007.03.029 · DOI
- Frisoni, 2007, Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy, Aging Clin Exp Res, 19, 349, 10.1007/BF03324714 · DOI
Cited by
Pathology and pathogenesis of vascular cognitive impairment—a critical update
Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353
“MORPHOLOGICAL SUBSTRATES OF VASCULAR COGNITIVE DISORDER VCI/VaD is the net result of vascular lesions that lead to impairment of brain function (Jellinger, 2007a, 2008a; Ferrer, 2010; Levine and Langa, 2011).”
BackgroundSolving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324
Exercise, cognitive function, and aging
Barnes, J. N. (2015) · Advances in Physiology Education · doi:10.1152/advan.00101.2014 · Cited by 283
Cerebrovascular pathology in Down syndrome and Alzheimer disease
Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009444.pub3 · Cited by 78
Metadata
- Authors
- Levine, D. A., & Langa, K. M.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 8
- Issue
- 3
- Pages
- 361-373
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2082094370
- Cited by
- 130
- References
- 56
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4435 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. https://app.cochat.ai/papers/10.1007/s13311-011-0047-z
- The paper
- Levine, D. A., & Langa, K. M. (2011). Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. Neurotherapeutics. https://doi.org/10.1007/s13311-011-0047-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.